Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.70 |
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.70 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.70 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 0.70 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.70 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.70 |
| ▸ | HTR1D known ✓ | P28221 | 2/20 | 0.64 |
| ▸ | HTR1B known ✓ | P28222 | 2/20 | 0.64 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.53 |
| ▸ | TACR1 known ✓ | P25103 | 2/20 | 0.53 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.52 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.51 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.50 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.50 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.50 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.50 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.50 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL471919 | 1.00 | NPSR1 (0.70) | NPSR1HTR2CHTR1AHTR2AHTR2B | |
| SCHEMBL6775810 | 0.99 | NPSR1 (0.72) | NPSR1HTR2CHTR1AHTR2AHTR2B | |
| SCHEMBL471920 | 0.99 | NPSR1 (0.72) | NPSR1HTR2CHTR1AHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL818356 | 0.89 | NPSR1 (0.69) | NPSR1HTR2CHTR1AHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL818357 | 0.89 | NPSR1 (0.69) | NPSR1HTR2CHTR1AHTR2AHTR2B | |
| SCHEMBL19357216 | 0.88 | HTR2C (0.76) | NPSR1HTR2CHTR1AHTR2AHTR2B | |
| SCHEMBL10903027 | 0.88 | NPSR1 (0.65) | NPSR1HTR2CHTR1AHTR2AHTR2B | |
| SCHEMBL816987 | 0.88 | NPSR1 (0.70) | NPSR1HTR2CHTR1AHTR2AHTR2B | |
| SCHEMBL10407437 | 0.88 | NPSR1 (0.70) | NPSR1HTR2CHTR1AHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL28173714 | 0.88 | TACR1 (0.56) | NPSR1HTR2CHTR1AHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163435-A | Intermediate compound for preparing tadalafil analogue containing sulfonyl fluoride group | 兰州大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-110498796-B | Tadalafil analogue containing sulfonyl fluoride group and synthesis method thereof | 兰州大学 | 2022-01-18 | — | — | CN | disclosed |
| CN-105073757-B | Dyeing process using a hair-dyeing precursor obtained from an iridoid, composition, precursor and device comprising such a precursor | 莱雅公司 | 2019-12-17 | — | — | CN | disclosed |
| WO-2014154871-A1 | DYEING PROCESS USING AN IRIDOID COMPOUND AND DEVICES FOR THE SAME | L'OREAL (FR) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013045704-A2 | DYE COMPOSITION COMPRISING A GLYCOSYL IRIDOID COMPOUND AND A PARTICULAR ALDEHYDE OR IMINE, DYEING PROCESS AND DEVICES THEREFOR | L'OREAL (FR) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013045701-A2 | DYEING PROCESS USING A COMPOSITION COMPRISING A GLYCOSYL IRIDOID COMPOUND AND A NUCLEOPHILE OR AN AMINO OR THIO POLYMER, COMPOSITION AND DEVICES THEREFOR | L'OREAL (FR) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013045702-A2 | DYE COMPOSITION COMPRISING A NON-GLYCOSYL IRIDOID COMPOUND AND A SPECIFIC NUCLEOPHILE OR AN AMINO OR THIO POLYMER, DYEING PROCESS, AND DEVICE THEREFOR | L'OREAL (FR) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013045703-A1 | DYE COMPOSITION COMPRISING A NON-GLYCOSYL IRIDOID COMPOUND AND A PARTICULAR ALDEHYDE OR IMINE, DYEING PROCESS AND DEVICE THEREFOR | L'OREAL (FR) | 2013-04-04 | — | — | WO | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| EP-1301487-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-11-22 | — | — | EP | disclosed |
| US-6716852-B2 | FOR THERAPY OF ARTERIAL HYPERTENSION AND CARDIOVASCULAR DISEASES | LES LABORATORIES SERVIER (FR) | 2004-04-06 | — | — | US | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| US-20030225092-A1 | Chemical compounds | LILLY ICOS LLC | 2003-12-04 | — | — | US | disclosed |
| US-20030055086-A1 | Amino acid derivatives and use thereof as nep, ace and ece inhibitors | LES LABORATOIRES SERVIER (FR) | 2003-03-20 | — | — | US | disclosed |
| EP-1289989-A2 | DERIVATIVES OF 2,3,6,7,12,12A-HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE | Lilly Icos LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| CN-1400974-A | Amino acid derivatives and use thereof as NEP, ACE and ECE inhibitors | INST NAT RECH MEDICALE INSERM (FR) | 2003-03-05 | — | — | CN | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| WO-2001094345-A2 | DERIVATIVES OF 2,3,6,7,12,12A-HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE | LILLY ICOS LLC (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225092-A1 | Chemical compounds | ABCG2, SDHA, CYP11B1 | HTR2C 2421/4885HTR1A 2303/4885HTR2A 3535/4885 |
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | HTR2C 2645/4885HTR1A 2508/4885HTR2A 4552/4885 |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | HAVCR2, HCCS, ZC3HAV1 | HTR2C 1797/4885HTR1A 1889/4885HTR2A 4472/4885 |
| US-20030055086-A1 | Amino acid derivatives and use thereof as nep, ace and ece inhibitors | MME, ACE, ECE1 | HTR2C 201/4885HTR1A 192/4885HTR2A 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.